News | July 31, 2025
Imfinzi granted Priority Review and Breakthrough Therapy Designation in US
For patients with resectable early-stage gastric and gastroesophageal junction cancers
For patients with resectable early-stage gastric and gastroesophageal junction cancers
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The INSPIRE-1 and INSPIRE-2 trials are Phase 3 studies assessing the efficacy and safety of tildrakizumab 100 mg (ILUMYA) in adults with active psoriatic arthritis (PsA)
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
Capricor’s BLA for Deramiocel received Priority Review in March 2025
LEQSELVI now available for prescription in U.S. nationwide, offering a new option for eligible patients
It is intended for contrast enhancement in MRI scans
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Subscribe To Our Newsletter & Stay Updated
